Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.44 |
| ▸ | UBE2N | P61088 | 1/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
| ▸ | YAP1 | P46937 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 4/20 | 0.41 |
| ▸ | PSMB11 | A5LHX3 | 3/20 | 0.41 |
| ▸ | PSMA7 | O14818 | 3/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.41 |
| ▸ | PSMA1 | P25786 | 3/20 | 0.41 |
| ▸ | PSMA2 | P25787 | 3/20 | 0.41 |
| ▸ | PSMA3 | P25788 | 3/20 | 0.41 |
| ▸ | PSMA4 | P25789 | 3/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.41 |
| ▸ | PSMB9 | P28065 | 3/20 | 0.41 |
| ▸ | PSMA5 | P28066 | 3/20 | 0.41 |
| ▸ | PSMB4 | P28070 | 3/20 | 0.41 |
| ▸ | PSMB6 | P28072 | 3/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29371746 | 0.99 | MAPK1 (0.45) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL20815350 | 0.99 | MAPK1 (0.45) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL23230085 | 0.99 | MAPK1 (0.45) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL598356 | 0.99 | MAPK1 (0.45) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL6840497 | 0.99 | MAPK1 (0.45) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL24868206 | 0.94 | ITGB1 (0.50) | MAPK1ITGB1ITGA4ITGB7YAP1 | |
| Potassium Ion SCHEMBL4648916 | 0.93 | UBE2N (0.41) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL3744009 | 0.91 | MAPK1 (0.44) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL22023402 | 0.91 | MAPK1 (0.44) | MAPK1ITGB1ITGA4UBE2NITGB7 | |
| SCHEMBL6480786 | 0.91 | MAPK1 (0.44) | MAPK1ITGB1ITGA4UBE2NITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867192-B1 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2005-03-15 | — | — | US | claimed |
| EP-1140837-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2004-08-18 | — | — | EP | claimed |
| EP-1140837-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2001-10-10 | — | — | EP | claimed |
| WO-2000037444-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2000-06-29 | — | — | WO | claimed |
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| EP-1701933-B1 | NOVEL COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-7410984-B2 | Compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20070043113-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1701933-A1 | NOVEL COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
| US-20050288337-A1 | Novel compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-12-29 | — | — | US | disclosed |
| WO-2005061440-A1 | NOVEL COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2005-07-07 | — | — | WO | disclosed |
| EP-1539696-A2 | PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES | TANABE SEIYAKU CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1289499-A1 | PHARMACEUTICAL ANTI-INFLAMMATORY AEROSOL FORMULATION | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| EP-1289497-A1 | NOVEL AQUEOUS ANTI-INFLAMMATORY PHARMACEUTICAL FORMULATION | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001095881-A1 | PHARMACEUTICAL ANTI-INFLAMMATORY AEROSOL FORMULATION | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001095925-A1 | PHARMACEUTICAL ANTI-INFLAMMATORY AEROSOL FORMULATION | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001095879-A1 | NOVEL AQUEOUS ANTI-INFLAMMATORY PHARMACEUTICAL FORMULATION | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001095885-A1 | DRY-POWDER PHARMACEUTICAL FORMULATION FOR INHALATION COMPRISING ALPHA4-INTERGRIN ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
| EP-1140837-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037444-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288337-A1 | Novel compounds | ITGB4, ITGA4, ITGB5 | MAPK1 2395/4885ITGB1 5/4885ITGA4 2/4885 |
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | ITGB4, ITGA4, ICAM1 | MAPK1 682/4885ITGB1 5/4885ITGA4 2/4885 |
| US-20070043113-A1 | Novel compounds | VCAM1, ICAM1, EPCAM | MAPK1 1560/4885ITGB1 198/4885ITGA4 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.